The University of Oxford announces it has dosed the first patients in a phase I study of NUC-7738

The Oxford Early Phase Clinical Trials Unit (EPCTU) announced that it has dosed the first cancer patients to receive NUC-7738. The clinical study NuTide:701 is a 2-part Phase I dose-escalation study in patients with advanced solid tumours. NUC 7738 is the third ProTide to enter the clinic from NuCana (NASDAQ: NCNA), a biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer.

NUC-7738 is a ProTide transformation of cordycepin or 3’-deoxyadenosine, a novel nucleoside analog isolated from the fungus Cordyceps sinensis in 1950, that has demonstrated potent anti-cancer activity in multiple non-clinical studies. As with NuCana’s other ProTides, NUC-7738 is designed to generate significantly higher levels of the active anti-cancer metabolite directly inside cells, bypassing the resistance mechanisms of transport, activation and breakdown.

Sarah Blagden, Associate Professor of Experimental Cancer Therapeutics at The University of Oxford and Principal Investigator of the NuTide:701 study stated: “We are particularly proud of this study as our own scientists continue to work on understanding of the mechanism of action of this exciting new agent. The application of NuCana’s ProTide chemistry, has created this new chemical entity and we look forward to seeing the results in patients” More information regarding this study can be found here.

Find out more about Oxford’s clinical trials below:

Study investigating targeted drug delivery by focused ultrasound for pancreatic cancer opens

University of Oxford researchers have begun recruitment to a study looking at whether chemotherapy medication can reach pancreatic tumours more effectively if encapsulated within a heat-sensitive shell and triggered with focused ultrasound.

Groundbreaking FOCUS4 clinical trials report their findings at ASCO

Principal Investigator Tim Maughan talks about the forward-thinking approach of the FOCUS4 cancer clinical trials and how they have helped shape the UK's fight against COVID-19

Being a part of cancer drug discoveries

Susan Cakebread, gives her account of being on an experimental drug trial here in Oxford

Innovative drug delivery techniques show promise in clinical trials

Dr Laura Spiers talks about the TarDox and PanDox trials, which are using novel drug delivery techniques to improve the uptake of chemotherapy drugs into pancreatic tumours and other cancers

Funding boost for OxPLoreD early detection study

UK Research and Innovation provides additional funds for whole genome sequencing as part of the OxPLoreD programme of research into high-risk conditions for blood cancer

What is a clinical trial? - new video series

What expect at every stage of an early phase clinical trial, so patients can make the most informed decision.